Prime-cord: precision research in inflammatory & ischemic myelopathies-cord consortium

Active Cooperative Agreement Awarded

Award ID
U54AI205727
Recipient
Awarding agency
Obligated
$1,379,043

Award facts

Completion date 4% complete
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, awarded Cooperative Agreement U54AI205727 to The Johns Hopkins University on Sep 9, 2026, with $1.379043 million obligated. The award falls under Assistance Listing 93.350, National Center for Advancing Translational Sciences.

The award funds the PRIME-CORD consortium (Precision Research in Inflammatory & Ischemic Myelopathies-CORD), which studies rare spinal cord disorders previously grouped under transverse myelitis and seeks to clarify their vascular, infectious, and autoimmune etiologies. The consortium pursues three initiatives: a natural history study of acute vascular myelopathies, including spinal cord stroke; a precision medicine characterization of infection- and immunization-associated and idiopathic myelitis; and an integrative genomics approach that examines genetic mechanisms linking neuromyelitis optica spectrum disorder (NMOSD) with systemic autoimmunity and identifies potential therapeutic targets for repurposing. Work relies on a national network of centers of excellence for timely patient recruitment and standardized data collection. The consortium builds on a partnership between the Johns Hopkins Myelitis and Myelopathy Center and the Siegel Rare Neuroimmune Association (SRNA).

The period of performance runs from the award date through an ultimate completion date of Jul 31, 2031. Place of performance is Baltimore, MD 21205.

Description

Abstract
The precision research in inflammatory & ischemic myelopathies (PRIME-CORD) consortium focuses on studies to understand, diagnose, and improve the management of rare spinal CORD disorders previously grouped under the term transverse myelitis (TM). Recognizing the limitations of this classification, the project aims to clarify the diverse etiologies of myelopathies, including vascular, infectious, and autoimmune causes, which complicate diagnosis and treatment. By leveraging recent advances in precision medicine, neuroimaging, genomics, and immunology, PRIME-CORD will advance our understanding of the underlying pathobiologic mechanisms, develop more effective evaluation methods, identify key risk factors, and ultimately establish targeted treatment strategies for conditions such as spontaneous acute vascular myelopathies or spinal CORD strokes, infection-associated myelitis, post-immunization myelitis, idiopathic myelitis, and neuromyelitis optica spectrum disorder (NMOSD). The consortium builds on a partnership between the johns hopkins myelitis and myelopathy center and the siegel rare neuroimmune association (SRNA), utilizing a national network of centers of excellence to facilitate timely patient recruitment and standardized data collection. The project encompasses three key scientific initiatives: 1) a natural history study of acute vascular myelopathies, 2) a precision medicine characterization of infection/immunization-associated and idiopathic myelitis, and 3) an integrative genomics approach aimed at identifying genetic mechanisms linking NMOSD with systemic autoimmunity and uncovering potential therapeutic targets for repurposing. Supported by comprehensive infrastructure, PRIME-CORD aims to elucidate clinical trajectories, define pathogenic mechanisms, translate molecular findings into therapeutic strategies, and cultivate the next generation of clinician-scientists dedicated to enhancing care for individuals with rare myelopathies.

Transactions

Action Obligated Date
Amendment $702,797
Original award $676,246

Quick answers

Who received award U54AI205727?

U54AI205727 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 9, 2026.

How much is award U54AI205727 worth?

$1,379,043 has been obligated on U54AI205727.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award